- cafead Dec 20, 2023 at 10:12: AM
via It's no secret that this year has been rough for smaller biotech companies searching for funds from venture capitalists. According to JLL Research, deals valued at less than $150 million have fallen by over 39% since 2022, while higher-value transactions have only fallen by 7.1% year over year.
article source
article source